TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AVANDIA CV Outcomes Study: Thiazolidinedione Intervention With Vitamin D Evaluation (TIDE) A Multicenter Randomized Double-Blind Placebo-Controlled Trial of a Thiazolidinedione or Placebo and of Vitamin D or Placebo In People With Type 2 Diabetes at Risk For Cardiovascular Disease
Brief Summary: This study will answer two separate questions.

The first question is to test the cardiovascular effects of long-term treatment with rosiglitazone or pioglitazone when used as part of standard of care compared to similar standard of care without rosiglitazone or pioglitazone in patients with type 2 diabetes who have a history of or are at risk for cardiovascular disease.

The second question will compare the effects of long-term supplementation of vitamin D on death and cancer


Options:
A: Intervention Type: DRUG; Name: cholecalciferol; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Physiotherapy; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D2 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D2 | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vitamin D2; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vitamin D2; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: Ia; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: calcium carbonate and cholecalciferol | Arm Label: Ib; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: calcium carbonate and cholecalciferol | Arm Label: IIa; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: IIb; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium carbonate and cholecalciferol; Assigned to Arm(s): Ia, Ib
D: Arm Label: pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: rosiglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: rosiglitazone | Arm Label: TZD placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D | Arm Label: Vitamin D placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): pioglitazone | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): rosiglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): TZD placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Vitamin D placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AVANDIA CV Outcomes Study: Thiazolidinedione Intervention With Vitamin D Evaluation (TIDE) A Multicenter Randomized Double-Blind Placebo-Controlled Trial of a Thiazolidinedione or Placebo and of Vitamin D or Placebo In People With Type 2 Diabetes at Risk For Cardiovascular Disease
Brief Summary: This study will answer two separate questions.

The first question is to test the cardiovascular effects of long-term treatment with rosiglitazone or pioglitazone when used as part of standard of care compared to similar standard of care without rosiglitazone or pioglitazone in patients with type 2 diabetes who have a history of or are at risk for cardiovascular disease.

The second question will compare the effects of long-term supplementation of vitamin D on death and cancer


Options:
A: Arm Label: Pioglitazone QD; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD
B: Arm Label: Aleglitazar; Type: EXPERIMENTAL; Interventions: Drug: Aleglitazar | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aleglitazar; Assigned to Arm(s): Aleglitazar | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: rosiglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: rosiglitazone | Arm Label: TZD placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D | Arm Label: Vitamin D placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): pioglitazone | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): rosiglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): TZD placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Vitamin D placebo
D: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients
Brief Summary: The purpose of this study is to determine if buprenorphine or methadone is better for the treatment of chronic pain among patients who have become addicted to prescription narcotics.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): 1, 2, 3
B: Arm Label: Probuphine; Type: EXPERIMENTAL; Interventions: Drug: Probuphine (buprenorphine implant) | Arm Label: placebo implant; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo implant | Arm Label: sublingual buprenorphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buprenorphine | Intervention Type: DRUG; Name: Probuphine (buprenorphine implant); Assigned to Arm(s): Probuphine | Intervention Type: DRUG; Name: placebo implant; Assigned to Arm(s): placebo implant | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): sublingual buprenorphine
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine/naloxone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Buprenorphine/naloxone; Assigned to Arm(s): 2
D: Arm Label: Methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Arm Label: Buprenorphine/naloxone; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine/naloxone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone | Intervention Type: DRUG; Name: Buprenorphine/naloxone; Assigned to Arm(s): Buprenorphine/naloxone

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients
Brief Summary: The purpose of this study is to determine if buprenorphine or methadone is better for the treatment of chronic pain among patients who have become addicted to prescription narcotics.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Clinic-based substance abuse treatment with buprenorphine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Case management and referred substance abuse treatment | Intervention Type: BEHAVIORAL; Name: Clinic-based substance abuse treatment with buprenorphine; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Case management and referred substance abuse treatment; Assigned to Arm(s): 2
B: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Probuphine | Arm Label: Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Probuphine; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Group B
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine/naloxone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Buprenorphine/naloxone; Assigned to Arm(s): 2
D: Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: Methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Buprenorphine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mindfulness-Based Stress Reduction for Posttraumatic Stress Disorder: A Pilot Study
Brief Summary: PTSD is a common consequence of war, for soldiers and civilians. PTSD results in hyperarousal, avoidance, numbing, and re-experiencing, causing persistent decreased quality of life. Mindfulness involves the ability to bring attention to the present moment without judgment; this ability is correlated with measures of mental health. Within health care, mindfulness is taught as an 8-week course called Mindfulness-Based Stress Reduction (MBSR). MBSR is unstudied for PTSD. We propose to assess the feasibility of MBSR as an intervention for PTSD, since it may affect hypervigilance, avoidance, and reactivity associated with this disorder.

Specific Aims: Aim 1: Assess the feasibility of recruiting and retaining a sample of veterans with PTSD to complete a study protocol that involves randomization to usual care or usual care plus MBSR. Aim 2: Apply measures of PTSD symptom severity, depression and quality of life before and after randomization, to assess whether there is evidence of benefit and whether MBSR warrants further study for PTSD, and allow calculation of standardized effect sizes. Aim 3: Apply a validated measure of mindfulness before and after treatment. Aim 4: Explore the relationship between PTSD symptoms, mindfulness score, and frequency of meditation practice.


Options:
A: Arm Label: MDMA-assisted therapy (125 mg); Type: EXPERIMENTAL; Interventions: Drug: Midomafetamine HCl, Behavioral: Therapy | Arm Label: Placebo with therapy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactose placebo pill, Behavioral: Therapy | Intervention Type: DRUG; Name: Midomafetamine HCl; Assigned to Arm(s): MDMA-assisted therapy (125 mg) | Intervention Type: DRUG; Name: Lactose placebo pill; Assigned to Arm(s): Placebo with therapy | Intervention Type: BEHAVIORAL; Name: Therapy; Assigned to Arm(s): MDMA-assisted therapy (125 mg), Placebo with therapy
B: Arm Label: MBSR; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based stress reduction | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness-based stress reduction; Assigned to Arm(s): MBSR
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: NET | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: NET; Assigned to Arm(s): A
D: Arm Label: study arm; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy treatment | Intervention Type: BEHAVIORAL; Name: Psychotherapy treatment; Assigned to Arm(s): study arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cost Effective Strategy to Evaluate Veterans With Sleep Apnea
Brief Summary: This research study is comparing home and in-laboratory testing of veterans with suspected obstructive sleep apnea, a common breathing disorder during sleep. It is hoped that home testing will be equally effective in improving quality of life but have lower cost than in-lab testing. These findings will allow veterans to have greater access to diagnosis and treatment of their sleep apnea.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard polysomnography (PSG) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Portable (Embla Embletta X30 system and Respironic REMStar Auto M series with CFlex) | Intervention Type: OTHER; Name: Portable (Embla Embletta X30 system and Respironic REMStar Auto M series with CFlex); Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Standard polysomnography (PSG); Assigned to Arm(s): 1
B: Arm Label: TLC-CPAP; Type: EXPERIMENTAL; Interventions: Device: Telecommunications system | Arm Label: TLC-Control; Type: PLACEBO_COMPARATOR; Interventions: Other: TLC-Control | Intervention Type: DEVICE; Name: Telecommunications system; Assigned to Arm(s): TLC-CPAP | Intervention Type: OTHER; Name: TLC-Control; Assigned to Arm(s): TLC-Control
C: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous positive airway pressure apparatus | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous positive airway pressure apparatus | Intervention Type: DEVICE; Name: Continuous positive airway pressure apparatus; Assigned to Arm(s): Arm 1, Arm 2
D: Arm Label: Standard care (SC); Type: SHAM_COMPARATOR; Interventions: Behavioral: CPAP education | Arm Label: Extended education (ME+SC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CPAP education | Intervention Type: BEHAVIORAL; Name: CPAP education; Assigned to Arm(s): Extended education (ME+SC), Standard care (SC)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study of 3 Dosages of JNJ-31001074 in the Treatment of Adult Subjects With Attention-Deficit/Hyperactivity Disorder
Brief Summary: The purpose of this study is to evaluate the efficacy and safety/tolerability of 3 different dosages of JNJ-31001074 compared with placebo in adult patients with attention-deficit/hyperactivity disorder (ADHD).


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: JNJ-31001074 1 mg/d | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: JNJ-31001074 3 mg/d | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: JNJ-31001074 10 mg/d | Arm Label: 004; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atomoxetine 80 mg/d | Arm Label: 005; Type: ACTIVE_COMPARATOR; Interventions: Drug: OROS methylphenidate HCl 54 mg/d | Arm Label: 006; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atomoxetine 80 mg/d; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 006 | Intervention Type: DRUG; Name: OROS methylphenidate HCl 54 mg/d; Assigned to Arm(s): 005 | Intervention Type: DRUG; Name: JNJ-31001074 3 mg/d; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: JNJ-31001074 1 mg/d; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: JNJ-31001074 10 mg/d; Assigned to Arm(s): 003
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: open label PR OROS methylphenidate | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: double blind PR OROS methylphenidate | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: double blind placebo | Intervention Type: DRUG; Name: double blind placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: double blind PR OROS methylphenidate; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: open label PR OROS methylphenidate; Assigned to Arm(s): 001
C: Arm Label: Ritalin LA 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Ritalin LA 20 mg | Arm Label: Ritalin LA 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Ritalin LA 20 mg, Drug: Ritalin LA 30 mg | Arm Label: Ritalin LA 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Ritalin LA 20 mg, Drug: Ritalin LA 30 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ritalin LA 20 mg; Assigned to Arm(s): Ritalin LA 40 mg, Ritalin LA 60 mg, Ritalin LA 80 mg | Intervention Type: DRUG; Name: Ritalin LA 30 mg; Assigned to Arm(s): Ritalin LA 60 mg, Ritalin LA 80 mg
D: Arm Label: Ritalin LA; Type: EXPERIMENTAL; Interventions: Drug: Ritalin LA (methylphenidate hydrochloride extended release) | Intervention Type: DRUG; Name: Ritalin LA (methylphenidate hydrochloride extended release); Assigned to Arm(s): Ritalin LA

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Evaluation of the Effectiveness of Ibuprofen and Opioid (Morphine or Diamorphine) for Acute Pain in Sickle Cell Disease: a Double-blind, Placebo-controlled Randomised Trial
Brief Summary: The use of oral ibuprofen combined with Opioid (Morphine or Diamorphine) administered through patient controlled analgesia (PCA) will be clinically effective for acute pain crisis in adults with sickle cell disease (SCD).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Eptifibatide | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eptifibatide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen, Drug: Diamorphine or Morphine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Diamorphine or Morphine | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Diamorphine or Morphine; Assigned to Arm(s): 1, 2
C: Arm Label: High Demand / Low Infusion; Type: OTHER; Interventions: Other: High Demand / Low Infusion | Arm Label: Low Demand / High Infusion; Type: OTHER; Interventions: Other: PCA Dosing Plan | Intervention Type: OTHER; Name: High Demand / Low Infusion; Assigned to Arm(s): High Demand / Low Infusion | Intervention Type: OTHER; Name: PCA Dosing Plan; Assigned to Arm(s): Low Demand / High Infusion
D: Arm Label: GMI-1070; Type: EXPERIMENTAL; Interventions: Drug: GMI-1070 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GMI-1070; Assigned to Arm(s): GMI-1070 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Immunogenicity of a Live, Attenuated Rotavirus Vaccine (RotaTeq™) in HIV-1 Infected and Uninfected Children Born to HIV-1-Infected Mothers
Brief Summary: Rotavirus is the leading cause of severe diarrhea in infants and young children, accounting for 45% of severe diarrhea disease in both developed and developing countries. Annually, rotavirus causes approximately 111 million episodes of gastroenteritis requiring home care, 25 million clinic visits, 2 million hospitalizations, and approximately 440,000 deaths in children less than 5 years of age, of which approximately 90% of hospitalizations and 99% of deaths occur in developing countries. Although rotavirus infection is not more common in HIV-infected children, it complicates their care and interferes with their nutrition. Chances of death by these infections can be greater in HIV-infected children when they also suffer from wasting, malnutrition, and/or opportunistic infections. The primary purpose of this study was to evaluate the safety and immunogenicity of the Rotavirus vaccine candidate, RotaTeq, in HIV-infected and uninfected children born to HIV-infected mothers.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Rotateq™ | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Intervention Type: BIOLOGICAL; Name: Rotateq™; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): 2
B: Arm Label: HIV-uninfected RotaTeq; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq | Arm Label: HIV-uninfected Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: HIV-infected RotaTeq; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq | Arm Label: HIV-1 infected Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: RotaTeq; Assigned to Arm(s): HIV-infected RotaTeq, HIV-uninfected RotaTeq | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): HIV-1 infected Placebo, HIV-uninfected Placebo
C: Intervention Type: BIOLOGICAL; Name: Rotavirus (vaccine); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: OTHER; Interventions: Biological: Rotateq vaccine | Intervention Type: BIOLOGICAL; Name: Rotateq vaccine; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: European Post Market Study: A Prospective, Randomized, Controlled, Multicenter Study to Evaluate the Performance of the IBV Valve System for the Treatment of Severe Emphysema
Brief Summary: The objective of this randomized, blinded, multicenter, controlled study is to compare the performance of the IBV Valve System (treatment group) to a control group receiving a sham bronchoscopy procedure without valve placement.


Options:
A: Arm Label: Medical management; Type: NO_INTERVENTION; Interventions: Device: IBV Valve | Intervention Type: DEVICE; Name: IBV Valve; Assigned to Arm(s): Medical management
B: Arm Label: BLVR Treatment; Type: EXPERIMENTAL; Interventions: Biological: BLVR Treatment | Intervention Type: BIOLOGICAL; Name: BLVR Treatment; Assigned to Arm(s): BLVR Treatment
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: awake nonresectional LVRS | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Nonawake resectional LVRS | Intervention Type: PROCEDURE; Name: awake nonresectional LVRS; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Nonawake resectional LVRS; Assigned to Arm(s): 2
D: Arm Label: Chartis System-EBV Treatment; Type: OTHER; Interventions: Device: Chartis System, Device: Endobronchial Valve (EBV) Treatment | Intervention Type: DEVICE; Name: Chartis System; Assigned to Arm(s): Chartis System-EBV Treatment | Intervention Type: DEVICE; Name: Endobronchial Valve (EBV) Treatment; Assigned to Arm(s): Chartis System-EBV Treatment

Answer: A